Payment overview · 2025
General Payments
$1,288.68
66 reported records · 21 companies
Healthcare provider profile · identity verified
Suzanne Rizkalla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOMA LINDA, CA · NPI 1043324742
Verified facts
What the public records show
CMS Open Payments records show Suzanne Rizkalla, M.D. received $1,288.68 in general payments during 2025 across 66 reported records.
Novo Nordisk Inc accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbyclor, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Edarbyclor by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 632 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $265.66 | 20.6% | 17 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $120.42 | 9.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $117.99 | 9.2% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.87 | 6.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.68 | 6.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.38 | 6.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.51 | 5.9% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.80 | 5.5% | 4 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $53.00 | 4.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.56 | 3.3% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.71 | 3.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.27 | 2.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.59 | 2.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $29.85 | 2.3% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $28.00 | 2.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.10 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.12 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.08 | 1.8% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $22.88 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.92 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.29 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,288.68 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.61 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $120.42 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $117.99 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $85.77 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.87 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.68 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $82.68 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $70.80 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.52 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.63 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.04 | 3 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $53.00 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.27 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.59 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBYCLOR edarbyclor |
2025 | Edarbyclor | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 632 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
354 | 58 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
632 | 103 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1300 | 366 |
| Levothyroxine Sodium | Levothyroxine Sodium | 985 | 234 |
| Gabapentin | Gabapentin | 928 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 909 | 240 |
| Pantoprazole Sodium | Pantoprazole Sodium | 688 | 182 |
| Losartan Potassium | Losartan Potassium | 683 | 173 |
| Diclofenac Sodium | Diclofenac Sodium | 644 | 90 |
| Ozempic | Semaglutide | 632 | 103 |
| Azithromycin | Azithromycin | 440 | 234 |
| Sertraline Hcl | Sertraline Hcl | 428 | 108 |
| Atenolol | Atenolol | 425 | 120 |
| Omeprazole | Omeprazole | 409 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 398 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 393 | 86 |
| Trazodone Hcl | Trazodone Hcl | 383 | 89 |
| Furosemide | Furosemide | 367 | 87 |
| Trulicity | Dulaglutide | 354 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 350 | 64 |
| Metformin Hcl | Metformin Hcl | 299 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 296 | 67 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 288 | 83 |
| Ibuprofen | Ibuprofen | 287 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 284 | 76 |
| Famotidine | Famotidine | 263 | 77 |
| Baclofen | Baclofen | 254 | 50 |
| Carvedilol | Carvedilol | 248 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 55 |
| Eliquis | Apixaban | 245 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 60 |
| Glipizide | Glipizide | 211 | 50 |
| Methylprednisolone | Methylprednisolone | 196 | 127 |
| Ondansetron Odt | Ondansetron | 193 | 44 |
| Glimepiride | Glimepiride | 189 | 44 |
| Potassium Chloride | Potassium Chloride | 189 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 47 |
| Tramadol Hcl | Tramadol Hcl | 183 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 172 | 110 |
| Metformin Hcl Er | Metformin Hcl | 172 | 49 |
| Jardiance | Empagliflozin | 170 | 32 |
| Ketoconazole | Ketoconazole | 164 | 51 |
| Metformin Er Gastric | Metformin Hcl | 164 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 164 | 32 |
| Simvastatin | Simvastatin | 164 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 47 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 158 | 32 |
| Lisinopril | Lisinopril | 153 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 39 |
| Finasteride | Finasteride | 143 | 36 |
| Dexlansoprazole Dr | Dexlansoprazole | 140 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 136 | 18 |
| Labetalol Hcl | Labetalol Hcl | 133 | 22 |
| Lidocaine | Lidocaine | 129 | 32 |
| Benazepril Hcl | Benazepril Hcl | 121 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 118 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 116 | 73 |
| Clonidine Hcl | Clonidine Hcl | 113 | 26 |
| Januvia | Sitagliptin Phosphate | 111 | 27 |
| Estradiol | Estradiol | 110 | 26 |
| Fluconazole | Fluconazole | 107 | 32 |
| Nifedipine Er | Nifedipine | 107 | 40 |
| Lorazepam | Lorazepam | 105 | 28 |
| Celecoxib | Celecoxib | 104 | 16 |
| Colchicine | Colchicine | 96 | 21 |
| Meclizine Hcl | Meclizine Hcl | 95 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 89 | 29 |
| Irbesartan | Irbesartan | 88 | 20 |
| Mirtazapine | Mirtazapine | 88 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 88 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 27 |
| Linzess | Linaclotide | 85 | 21 |
| Mounjaro | Tirzepatide | 85 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 24 |
| Cephalexin | Cephalexin | 81 | 52 |
| Alprazolam | Alprazolam | 80 | 13 |
| Methocarbamol | Methocarbamol | 79 | 20 |
| Entresto | Sacubitril/Valsartan | 78 | 15 |
| Xarelto | Rivaroxaban | 78 | 15 |
| Allopurinol | Allopurinol | 75 | 21 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 75 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 73 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 73 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 72 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 28 |
| Promethazine Hcl | Promethazine Hcl | 71 | 40 |
| Spironolactone | Spironolactone | 71 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 19 |
| Lactulose | Lactulose | 69 | 22 |
| Repatha Sureclick | Evolocumab | 69 | suppressed |
| Acyclovir | Acyclovir | 67 | 19 |
| Olanzapine | Olanzapine | 66 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 65 | 14 |
| Synthroid | Levothyroxine Sodium | 64 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 16 |
| Donepezil Hcl | Donepezil Hcl | 61 | 13 |
| Warfarin Sodium | Warfarin Sodium | 61 | 11 |
| Edarbi | Azilsartan Medoxomil | 60 | 11 |
| Prednisone | Prednisone | 60 | 20 |
| Valsartan | Valsartan | 60 | 22 |
| Montelukast Sodium | Montelukast Sodium | 59 | 17 |
| Hydrocortisone | Hydrocortisone | 58 | 21 |
| Levetiracetam | Levetiracetam | 58 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 56 | 16 |
| Nitroglycerin | Nitroglycerin | 55 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 55 | suppressed |
| Temazepam | Temazepam | 55 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 55 | suppressed |
| Clonazepam | Clonazepam | 54 | suppressed |
| Latanoprost | Latanoprost | 54 | suppressed |
| Meloxicam | Meloxicam | 54 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 50 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Metronidazole | Metronidazole | 47 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 17 |
| Alogliptin | Alogliptin Benzoate | 45 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | suppressed |
| Pregabalin | Pregabalin | 44 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Fenofibrate | Fenofibrate | 42 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Tadalafil | Tadalafil | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Progesterone | Progesterone, Micronized | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 37 | suppressed |
| Prolia | Denosumab | 36 | 24 |
| Valacyclovir | Valacyclovir Hcl | 36 | 14 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Naproxen | Naproxen | 34 | 15 |
| Single Use Swab | Alcohol Antiseptic Pads | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 30 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 11 |
| Ofloxacin | Ofloxacin | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 24 |
| Amoxicillin | Amoxicillin | 26 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Trulance | Plecanatide | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | 13 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Ssd | Silver Sulfadiazine | 20 | 11 |
| Tacrolimus | Tacrolimus | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,288.68 · 66 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBYCLOR, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Kerendia, LEQVIO, MOUNJARO, NP Thyroid 60, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TEPEZZA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, Xhance, Yorvipath, ZAVZPRET, ZEPBOUND | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbyclor play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error